Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trialDaniel V.T. Catenacci, Yung‐Jue Bang, Philip J. Gold et al.|The Lancet Oncology|2020Cited by 190
EGFR endocytosis is a novel therapeutic target in lung cancer with wild-type EGFRUkhyun Jo, Yeul Hong Kim|Oncotarget|2014Cited by 58
A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancerDaisuke Sakai, Toshihiko Doi, Hyun Cheol Chung et al.|Cancer Chemotherapy and Pharmacology|2017Cited by 31
Identification of different gene expressions between diffuse- and intestinal-type spheroid-forming gastric cancer cellsJong Won Lee, Yeul Hong Kim|Gastric Cancer|2019Cited by 11